ArticleCardiovascular drugs and therapy2026
Berberine Attenuates Hypertrophic Phenotype in RAF1-Mutant Induced Pluripotent Stem Cell-Derived Cardiomyocytes through Suppression of ERK5-Cyclin D1 Signaling.
Article in Cardiovascular drugs and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundNoonan syndrome-associated hypertrophic cardiomyopathy (NS-HCM) occurs frequently in patients with RAF1 mutations, but the signaling mechanisms underlying the hypertrophic cardiomyocyte phenotype remain incompletely understood, and effective therapeutic targets remain to be defined. This study aimed to characterize MAPK signaling dysregulation in RAF1-mutant induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) and to determine whether berberine (BBR) attenuates the hypertrophic phenotype through modulation of ERK5-Cyclin D1 signaling.
methodsAn in vitro NS-HCM cardiomyocyte model was established using induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) from a patient harboring the RAF1 p.Ser257Leu mutation. Wild-type iPSC-CMs were generated from healthy donors. Immunofluorescence was used to assess cardiomyocyte surface area, sarcomeric organization, and Ki-67/EdU-based cell-cycle activity. Transcriptomic analyses of public NS-HCM datasets were performed to identify differentially expressed genes and enriched pathways. Western blotting was performed to evaluate the activation of MEK1/2-ERK1/2 and ERK5 signaling pathways, downstream Cyclin D1 expression, and hypertrophic markers including ANP and BNP. RAF1
resultsRAF1
conclusionRAF1-mutant iPSC-CMs exhibited concurrent activation of the MEK1/2-ERK1/2 and ERK5-Cyclin D1 signaling pathways. BBR attenuated the hypertrophic phenotype while reducing ERK5 phosphorylation and Cyclin D1 expression without significantly altering MEK1/2-ERK1/2 signaling. These findings suggest that ERK5-Cyclin D1 signaling contributes to the hypertrophic phenotype of RAF1-mutant cardiomyocytes and support further investigation of BBR as a potential therapeutic candidate for RAF1-associated NS-HCM.
Indexed as
Identifiers
42667574What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.